ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,858Medicare Part D Prescriptions Filled, Including Refills

Rank: 25 out of 823

$910K Total Retail Price of All Prescriptions

Rank: 28 out of 823

515 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
78% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

12% of this provider’s 515 patients filled at least one prescription for a schedule three drug, compared to an average of 18%.

Risky Drugs to Seniors

2% of this provider’s 7,978 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 3%.

Brand Name Drugs

36% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$92 was the average price of a prescription from this provider, compared to $103 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
SIMVASTATIN 368 324 1 2
LEVOTHYROXINE SODIUM 355 300 2 6
NEXIUM 249 226 3 10
AMLODIPINE BESYLATE 228 220 4 3
METOPROLOL SUCCINATE 226 191 5 9
ATORVASTATIN CALCIUM 203 173 6 13
CRESTOR 203 163 6 20
HYDROCODONE-ACETAMINOPHEN 194 149 S3 8 1
LISINOPRIL 171 148 9 4
METFORMIN HCL ER 163 145 10 94
OMEPRAZOLE 156 110 11 5
SERTRALINE HCL 144 134 12 38
FUROSEMIDE 143 126 13 7
DONEPEZIL HCL 141 141 14 24
ALENDRONATE SODIUM 122 93 15 42
TRAMADOL HCL 118 96 16 15
METFORMIN HCL 114 86 17 14
ENALAPRIL MALEATE 108 92 18 62
CITALOPRAM HBR 107 88 19 34
QUETIAPINE FUMARATE 102 87 20 73
LOSARTAN POTASSIUM 99 84 21 26
CLOPIDOGREL 98 94 22 16
TAMSULOSIN HCL 97 96 23 21
POTASSIUM CHLORIDE 96 93 24 22
GLIMEPIRIDE 95 65 25 51
RAMIPRIL 94 81 26 69
CYMBALTA 88 57 27 40
NAMENDA 87 86 28 28
HYDROCHLOROTHIAZIDE 84 76 29 29
LEVOFLOXACIN 82 75 30 101
CELEBREX 75 70 31 115
MELOXICAM 69 64 32 27
ZOLPIDEM TARTRATE 69 47 32 17
DIOVAN 68 64 34 35
WARFARIN SODIUM 64 64 35 18
CARVEDILOL 62 57 36 12
AZITHROMYCIN 61 38 37 48
DIOVAN HCT 60 54 38 79
ACTOS 59 36 39 130
GLYBURIDE-METFORMIN HCL 58 51 R 40 121
GABAPENTIN 56 32 41 8
ISOSORBIDE MONONITRATE ER 56 49 41 49
ESCITALOPRAM OXALATE 56 47 41 99
VENLAFAXINE HCL ER 55 41 44 163
METOPROLOL TARTRATE 55 37 44 11
TRICOR 53 39 46 150
GLYBURIDE 53 53 R 46 150
BYSTOLIC 53 40 46 98
KOMBIGLYZE XR 53 31 46 508
PAROXETINE HCL 52 51 50 175
ENOXAPARIN SODIUM 50 50 51 418
ALLOPURINOL 50 35 51 61
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 6, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.